Pharmacovigilance-related recommendations to product information for centrally authorised veterinary medicines

The European Medicines Agency's (EMA) Committee for Veterinary Medicinal Products (CVMP) issues recommendations on updating the product information for centrally authorised veterinary medicines, based on an evaluation of safety data. The marketing authorisation holder of the medicine is responsible for implementing these CVMP recommendations.

EMA maintains a document compiling all CVMP recommendations for product information updates each year. EMA updates the document each month to reflect the latest recommendations following CVMP plenary meetings.

This aims to ensure stakeholders have timely access to the latest recommended product information updates for the safe and efficacious use of veterinary medicines.

For more information on specific medicines, visit the Veterinary Medicines Information website.

Recommendations

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2024

Reference Number: EMA/CVMP/PhVWP/75148/2024

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2023

Reference Number: EMA/CVMP/PhVWP/137199/2023

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2022

Reference Number: EMA/CVMP/PhVWP/48138/2022

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2021

Reference Number: EMA/CVMP/PhVWP/105691/2021Summary:

November 2021

Pharmacovigilance regulatory recommendations for centrally authorised veterinary medicinal products during 2020

Reference Number: EMA/112926/2020Summary:

This document is updated monthly with the Committee for Medicinal Products for Veterinary Use (CVMP) recommendations for regulatory actions based on pharmacovigilance data. It must be noted that the recommendations to product information may not reflect the final wording and may also change in the course of the review before implementation by marketing authorisation holders.